Japanese | English

トップページへ戻る

詳細

   
フルテキストURLA020051000303.pdf ( 291.4KB ) 公開日 2010-04-19
タイトルThe Current Status and Issues Concerning Monoclonal Antibody Therapy
作成者Hinoda, Yuji
作成者ヨミヒノダ, ユウジ
作成者所属山口大学医学部
内容記述(抄録等)Monoclomal antibodies (mAbs) against growth factor or its receptor have raised the second wave of antibody therapy for solid tumors. Transtuzumab (humanized anti-HER2mAb) is the first mAb approved for the treatment of a solid tumor, metastatic breast cancer. Large-scale phase Ⅲ clinical trials are now ongoing to further evaluate the additive effects on chemotherapy and the efficacy as a maintenance monotherapy. Overexpression of HER2 is found only a small percentage of patients with solid tumor, whereas epidermal growth factor receptor is expressed in a variety of solid tumors with high frequency. More broadly applicable for solid tumors is anti-angiogenesis therapy because it is targeting not tumor cells but tumor vasculature. Cetuximab (chimeric anti-EGFR mAb) and bevacizumab (humanized anti-VEGF mAb)have recently been shown to be clinically of remarkable effect for metastatic colorectal cancer. The points at issue are thrombotic events of bevacizumab. In contrast to the mAbs as signal inhibitors, no apparent objective responses were seen in most clinical studies of mAbs against cell surface glycoproteins or adhesion molecules. However, several groups reported the survival benefit of those mAbs, in which anti-idiotypic antibody response may play an important role. In addition, some of their anti-idiotype mAbs showed the survival benefit in patients with solid tumor. Altered self-antigens have recently been attempted to intensify active immunotherapy including dendritic cell therapy. Considering that dendritic cells efficientry cross-present tumor antigens after ingesting them as immune complex those ”modest″ mAbs may be of use for dendritic cell therapy as immune complex with altered self-antigens.
本文言語eng
著者キーワードmonoclonal antibody
HER2
epidermal growth factor receptor
vascular endothelial growth factor
VEGF receptor
human anti-mouse antibody
epithelial cell adhesion molecule
cytotoxic T lymphocyte-associated antigen 4
dendritic cells
主題医学
資料タイプtext
ファイル形式application/pdf
出版者Yamaguchi University Graduate School of Medicine
NII資料タイプ紀要論文
ISSN0513-1812
NCIDAA00594272
学内刊行物(紀要等)The bulletin of the Yamaguchi Medical School
掲載誌名The bulletin of the Yamaguchi Medical School
掲載誌名別表記山口医科大学紀要
51
3-4
開始ページ41
終了ページ50
発行日2004-12
著者版/出版社版出版社版
リポジトリIDA020051000303
地域区分山口大学
URIhttp://www.lib.yamaguchi-u.ac.jp/yunoca/handle/A020051000303